Small molecule inhibitors of BTK including ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, are FDA-approved for the treatment of relapsed/refractory MCL and provide significant clinical benefits for a period of time. The gene discussed is BTK; the disease is mantle cell lymphoma.